Trends in research related to vaccine and cancer prevention from 1992 to 2022: A 30-years bibliometric analysis

References

• Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chinese Med J-Peking. 2021;134(7):1–11. doi:10.1097/CM9.0000000000001474.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin. 2021;71(3):209–49. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Enokida T, Moreira A, Bhardwaj N. Vaccines for immunoprevention of cancer. J Clin Invest. 2021;131(9). doi:10.1172/JCI146956.
   PubMed Web of Science ®Google Scholar
• Bray F, Jemal A, Torre LA, Forman D, Vineis P. Long-term realism and cost-effectiveness: primary prevention in combatting cancer and associated inequalities worldwide. JNCI-J Natl Cancer I. 2015;107(12):v273. doi:10.1093/jnci/djv273.
   Web of Science ®Google Scholar
• Bray F, Soerjomataram I. The changing global burden of cancer: transitions in human development and implications for cancer prevention and control. 2015.
   Google Scholar
• Li Q, Yang W, Li J, Shan Z. Emerging trends and hot spots in autoimmune thyroiditis research from 2000 to 2022: a bibliometric analysis. Front Immunol. 2022;13:953465. doi:10.3389/fimmu.2022.953465.
   PubMed Web of Science ®Google Scholar
• Finn OJ, Edwards RP. Human papillomavirus vaccine for cancer prevention. New Engl J Med. 2009;361(19):1899–901. doi:10.1056/NEJMe0907480.
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New Engl J Med. 2015;372(8):711–23. doi:10.1056/NEJMoa1405044.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99. doi:10.1016/S1470-2045(11)70286-8.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–14. doi:10.1016/S0140-6736(09)61248-4.
   PubMed Web of Science ®Google Scholar
• Shi JF, Cao M, Wang Y, Bai FZ, Lei L, Peng J, Feletto E, Canfell K, Qu C, Chen W. Is it possible to halve the incidence of liver cancer in China by 2050? Int J Cancer. 2021;148(5):1051–65. doi:10.1002/ijc.33313.
   PubMed Web of Science ®Google Scholar
• Lebossé F, Zoulim F. Hepatitis B vaccine and liver cancer. B Cancer. 2021;108(1):90–101. doi:10.1016/j.bulcan.2020.10.014.
   Google Scholar
• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4–13. doi:10.1002/hep.31288.
   PubMed Web of Science ®Google Scholar
• Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature. Hum Vacc Immunother. 2019;15(1):146–55. doi:10.1080/21645515.2018.1512453.
   PubMed Web of Science ®Google Scholar
• Tran BX, Pham TV, Ha GH, Ngo AT, Nguyen LH, Vu T, Do H, Nguyen V, Nguyen A, Tran T, et al. A bibliometric analysis of the global research trend in child maltreatment. Int J Env Res Pub He. 2018;15(7):1456. doi:10.3390/ijerph15071456
   Web of Science ®Google Scholar
• Luo H, Cai Z, Huang Y, Song J, Ma Q, Yang X, Song Y Study on pain catastrophizing from 2010 to 2020: a bibliometric analysis via citespace. Front Psychol. 2021;12:759347. doi:10.3389/fpsyg.2021.759347.
   PubMed Web of Science ®Google Scholar
• Amin MN, Ahmad W, Khan K, Sayed MM. Mapping research knowledge on rice husk ash application in concrete: a scientometric review. Materials. 2022;15(10):3431. doi:10.3390/ma15103431.
   PubMed Web of Science ®Google Scholar
• Wei N, Xu Y, Li Y, Shi J, Zhang X, You Y, Sun Q, Zhai H, Hu Y. A bibliometric analysis of T cell and atherosclerosis. Front Immunol. 2022;13:948314. doi:10.3389/fimmu.2022.948314.
   PubMedGoogle Scholar
• Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. P Natl Acad Sci USA. 2004;101 (Suppl 1):5303–10. doi:10.1073/pnas.0307513100.
   PubMed Web of Science ®Google Scholar
• Martín-Martín A, Thelwall M, Orduna-Malea E, Delgado LE. Google scholar, Microsoft academic, Scopus, dimensions, web of science, and OpenCitations’ COCI: a multidisciplinary comparison of coverage via citations. Scientometrics. 2021;126(1):871–906. doi:10.1007/s11192-020-03690-4.
   PubMed Web of Science ®Google Scholar
• Xu D, Wang YL, Wang KT, Wang Y, Dong XR, Tang J, Cui Y-L. A scientometrics analysis and visualization of depressive disorder. Curr Neuropharmacol. 2021;19(6):766–86. doi:10.2174/1570159X18666200905151333.
   PubMed Web of Science ®Google Scholar
• Tang C, Liu D, Fan Y, Yu J, Li C, Su J, Wang C. Visualization and bibliometric analysis of cAMP signaling system research trends and hotspots in cancer. J Cancer. 2021;12(2):358–70. doi:10.7150/jca.47158.
   PubMed Web of Science ®Google Scholar
• Shi Y, Wei W, Li L, Wei Q, Jiang F, Xia G, Yu H. The global status of research in breast cancer liver metastasis: a bibliometric and visualized analysis. Bioengineered. 2021;12(2):12246–62. doi:10.1080/21655979.2021.2006552.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247–55. doi:10.1016/S0140-6736(06)68439-0.
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. New Engl J Med. 2002;347(21):1645–51. doi:10.1056/NEJMoa020586.
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan J, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New Engl J Med. 2007;356(19):1928–43. doi:10.1056/NEJMoa061760
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757–65. doi:10.1016/S0140-6736(04)17398-4.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–8. doi:10.1016/S1470-2045(05)70101-7.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter DL, Kitchener HC, Castellsague X, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161–70. doi:10.1016/S0140-6736(07)60946-5.
   PubMed Web of Science ®Google Scholar
• Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121(3):621–32. doi:10.1002/ijc.22527.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson S-E, Høye J, Steinwall M, Riis-Johannessen G, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Brit J Cancer. 2006;95(11):1459–66. doi:10.1038/sj.bjc.6603469.
   PubMed Web of Science ®Google Scholar
• Villa L, Perez G, Kjaer S, Paavonen J. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New Engl J Med. 2007;356:1915–27.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70. doi:10.1002/ijc.30716.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203. doi:10.1016/S2214-109X(19)30482-6.
   PubMed Web of Science ®Google Scholar
• Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the advisory committee on immunization practices. MMWR-Morbid Mortal W. 2016;65(49):1405–8. doi:10.15585/mmwr.mm6549a5.
   PubMed Web of Science ®Google Scholar
• Drolet M, Bénard É, Pérez N, Brisson M, Ali H, Boily M-C, Baldo V, Brassard P, Brotherton JML, Callander D, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497–509. doi:10.1016/S0140-6736(19)30298-3.
   PubMed Web of Science ®Google Scholar
• Walker TY, Elam-Evans LD, Singleton JA, Yankey D, Markowitz LE, Fredua B, Williams CL, Meyer SA, Stokley S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years — United States, 2016. MMWR-Morbid Mortal W. 2017;66(33):874–82. doi:10.15585/mmwr.mm6633a2.
   PubMed Web of Science ®Google Scholar
• Ma D, Yang B, Guan B, Song L, Liu Q, Fan Y, Zhao L, Wang T, Zhang Z, Gao Z, et al. A bibliometric analysis of pyroptosis from 2001 to 2021. Front Immunol. 2021;12:731933. doi:10.3389/fimmu.2021.731933.
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin H-R, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56. doi:10.1016/S1470-2045(10)70230-8.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Dehlendorff C, Belmonte F, Baandrup L. Real-world effectiveness of human papillomavirus vaccination against cervical cancer. JNCI-J Natl Cancer I. 2021;113(10):1329–35. doi:10.1093/jnci/djab080.
   Web of Science ®Google Scholar
• Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, Sundström K, Dillner J, Sparén P. HPV vaccination and the risk of invasive cervical cancer. New Engl J Med. 2020;383(14):1340–8. doi:10.1056/NEJMoa1917338.
   PubMed Web of Science ®Google Scholar
• Petrosky E, Bocchini JJ, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR-Morbid Mortal W. 2015;64(11):300–4.
   PubMed Web of Science ®Google Scholar
• Drolet M, Laprise JF, Martin D, Jit M, Bénard É, Gingras G, Boily M-C, Alary M, Baussano I, Hutubessy R, et al. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. Lancet Infect Dis. 2021;21(11):1598–610. doi:10.1016/S1473-3099(20)30860-4.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao Q, Zhao B, Zheng Y, Zhuang Q, Liao N, Wang P, Cai Z, Zhang D, Zeng Y, et al. Remodeling tumor-associated neutrophils to enhance dendritic cell-based HCC neoantigen nano-vaccine efficiency. Adv Sci. 2022;9(11):e2105631. doi:10.1002/advs.202105631.
   Web of Science ®Google Scholar
• Kumbhar P, Kole K, Khadake V, Marale P, Manjappa A, Nadaf S, Jadhav R, Patil A, Singh SK, Dua K, et al. Nanoparticulate drugs and vaccines: breakthroughs and bottlenecks of repurposing in breast cancer. J Control Release. 2022;349:812–30. doi:10.1016/j.jconrel.2022.07.039.
   PubMed Web of Science ®Google Scholar
• Gan J, Du G, He C, Jiang M, Mou X, Xue J, Sun X Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination. J Control Release. 2020;326:297–309. doi:10.1016/j.jconrel.2020.07.008.
   PubMed Web of Science ®Google Scholar
• Bayó C, Jung G, Español-Rego M, Balaguer F, Benitez-Ribas D. Vaccines for non-viral cancer prevention. Int J Mol Sci. 2021;22(20):10900. doi:10.3390/ijms222010900.
   PubMed Web of Science ®Google Scholar
• Finn OJ. The dawn of vaccines for cancer prevention. Nat Rev Immunol. 2018;18(3):183–94. doi:10.1038/nri.2017.140.
   PubMed Web of Science ®Google Scholar
• Alam S, Hasan MK, Manjur O, Khan AM, Sharmin Z, Pavel MA, Hossain MF Predicting and designing epitope ensemble vaccines against HTLV-1. J Integr Bioinformat. 2020;16(4). doi:10.1515/jib-2018-0051.
   PubMed Web of Science ®Google Scholar
• van Zyl DG, Mautner J, Delecluse HJ. Progress in EBV vaccines. Front Oncol. 2019;9:104. doi:10.3389/fonc.2019.00104.
   PubMed Web of Science ®Google Scholar